ABBOTT PARK, Ill., June 3, 2021
/PRNewswire/ -- Abbott (NYSE: ABT) today announced the
company has capacity and supply to effectively support the growing
demand for mechanical circulatory support (MCS) devices for the
effective treatment of advanced heart failure following Medtronic's
decision to stop the global distribution and sale of the Medtronic
HeartWare™ ventricular assist device (HVAD). Abbott is also
supporting training and education programs for additional
physicians who will now be offering Abbott's HeartMate 3™ heart
pumps to their patients.
For patients with advanced heart failure who are either awaiting
a heart transplant or not eligible for transplantation, left
ventricular assist devices (LVADs) remain a critical option that
can extend survival and restore quality of life. To support
patients and their physicians, Abbott's HeartMate 3 heart pump is
available to physicians and patients around the world in markets
where the technology has been approved for use.
"For years we have seen truly life-saving results in patients
treated with mechanical circulatory support devices. Ensuring
continued access to these devices is critical for patients," said
Mike Pederson, senior vice president
of Abbott's electrophysiology and heart failure business. "We are
working to ensure that physicians have the support and training
they need as they further adopt HeartMate 3 to improve outcomes for
their advanced heart failure patients."
Abbott's HeartMate 3 heart pump is a small, implantable
mechanical circulatory support device for advanced heart failure
patients requiring either short- or long-term support who are
awaiting a heart transplant or who are not candidates for heart
transplantation. The pump has a proven mortality benefit and strong
safety profile that has led to longer, improved lives for thousands
of advanced heart failure patients around the world. In a recent
study of risk adjusted and propensity matched patients supported
with the HeartMate 3 published in the Annals of Thoracic Surgery,
actuarial survival rates were found to be 87% at one year and 84%
at two years.
In addition to extending the lives of patients with advanced
heart failure, Abbott's HeartMate 3 heart pump can significantly
improve quality of life and reduce adverse events. In addition,
HeartMate 3 is approved for pediatric use. To date, nearly 18,000
patients around the world have been supported by the HeartMate 3
heart pump.
For more information on Abbott's market-leading heart failure
portfolio, please
visit: https://www.cardiovascular.abbott.
About Abbott:
Abbott is a global healthcare leader
that helps people live more fully at all stages of life. Our
portfolio of life-changing technologies spans the spectrum of
healthcare, with leading businesses and products in diagnostics,
medical devices, nutritionals and branded generic medicines. Our
109,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn
at www.linkedin.com/company/abbott-/, on Facebook
at www.facebook.com/Abbott and on
Twitter @AbbottNews.
View original
content:http://www.prnewswire.com/news-releases/abbott-confirms-capacity-to-support-expanded-use-of-heartmate-3-heart-pump-301305002.html
SOURCE Abbott